Under the Medicare GLP-1 Bridge, eligible beneficiaries can get Medicare coverage of GLP-1s for obesity for a $50 monthly copayment, which will not count towards the Part D deductible or out-of-pocket spending cap and Part D Low-Income Subsidy cost-sharing assistance will not apply
operations said that they had started to see a slight reduction in the food basket purchased by those using Wegovy and other weight-loss drugs
Metabolic improvements: Additional benefits noted in research settings include reduction in waist circumference, improved lipid profiles, and decreased markers of insulin resistance
These medications help regulate blood sugar levels and reduce appetite
Hepatic benefits include reduced oxidative stress, inflammation, and improved liver enzyme profiles (ALT, hsCRP), as well as enhanced antioxidant enzyme levels, thereby protecting against acute liver injury
Phase 3 outcomes are not yet published